Suppr超能文献

通过鲎试剂检测证明生物制品中不存在细菌内毒素掩盖效应。

Evidence against a bacterial endotoxin masking effect in biologic drug products by limulus amebocyte lysate detection.

作者信息

Bolden Jay S, Claerbout Mark E, Miner Matthew K, Murphy Marie A, Smith Kelly R, Warburton Rob E

机构信息

Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN

Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN.

出版信息

PDA J Pharm Sci Technol. 2014 Sep-Oct;68(5):472-7. doi: 10.5731/pdajpst.2014.00999.

Abstract

UNLABELLED

The inability to detect endotoxin using compendia methods is a potential safety concern for patients due to the lack of endotoxin removal capabilities at the fill-finish stage in typical aseptic biologic drug product manufacturing. We have successfully demonstrated endotoxin challenge study recovery methodology using mammalian cell-produced biologic drug products and drug substances in citrate, histidine, phosphate, and sodium acetate buffer formulations containing polysorbate, challenged with an endotoxin analyte, for up to 6 months of storage. Successful recovery was similarly demonstrated for a preserved, peptide-containing drug product formulation. To isolate a potential masking-or low-endotoxin recovery-source, additional studies were performed to evaluate factors including product manufacturing contact surfaces, drug product matrix with and without polysorbate, individual matrix components, protein concentration, reagent suppliers, an orthogonal test method, and storage conditions. In all cases, acceptable recoveries were observed. Bacterial endotoxin is known to be chemically stable at physiological conditions. Purified endotoxin in aqueous conditions is likely to self-aggregate or bind to surfaces. Neither the nature of, nor the storage conditions of, the studied formulation matrices were shown experimentally to render the challenge endotoxin biologically inactive. The results highlight the importance of appropriate study design in assessing the recovery of endotoxins.

LAY ABSTRACT

Bacterial endotoxin is a Gram-negative bacterial cell wall component that is harmful to humans at threshold concentrations, and it is not expected to be in aseptically-produced pharmaceutical medicines. It has been suggested that endotoxin cannot be detected over time in certain biopharmaceutical drug product formulations containing citrate, phosphate, and polysorbate components via an unknown masking mechanism. We have generated and present data here that indicate that endotoxin can be recovered in a variety of matrices, and under various experimental conditions.

摘要

未标记

由于在典型的无菌生物药品生产的灌封阶段缺乏内毒素去除能力,使用药典方法无法检测到内毒素对患者来说是一个潜在的安全问题。我们已经成功地证明了使用哺乳动物细胞生产的生物药品和原料药,在含有聚山梨酯的柠檬酸盐、组氨酸、磷酸盐和醋酸钠缓冲液配方中,用内毒素分析物进行挑战,并储存长达6个月的内毒素挑战研究回收率方法。对于一种保存的含肽药品配方,也同样证明了成功回收。为了分离潜在的掩盖或低内毒素回收来源,进行了额外的研究,以评估包括产品生产接触表面、有无聚山梨酯的药品基质、单个基质成分、蛋白质浓度、试剂供应商、正交试验方法和储存条件等因素。在所有情况下,都观察到了可接受的回收率。已知细菌内毒素在生理条件下化学稳定。水性条件下的纯化内毒素可能会自聚集或与表面结合。实验表明,所研究的配方基质的性质和储存条件均未使挑战内毒素失去生物活性。结果强调了在评估内毒素回收率时进行适当研究设计的重要性。

摘要

细菌内毒素是革兰氏阴性细菌细胞壁的一种成分,在阈值浓度下对人类有害,预计无菌生产的药品中不应含有。有人提出,通过一种未知的掩盖机制,在某些含有柠檬酸盐、磷酸盐和聚山梨酯成分的生物制药产品配方中,随着时间的推移无法检测到内毒素。我们在此生成并展示的数据表明,内毒素可以在多种基质中以及在各种实验条件下回收。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验